Neurophet partners with Spain’s VHIR to boost AI‑driven multiple sclerosis imaging. The Seoul‑based AI‑diagnostics firm announced a research alliance with the Vall d’Hebron Institut de Recerca (VHIR) to co‑develop and validate deep‑learning models that detect multiple sclerosis (MS) lesions on magnetic resonance imaging (MRI). The joint effort will feed Neurophet’s AQUA MS software with more than 1,000 de‑identified, expertly annotated brain scans, targeting the Central Vein Sign and Paramagnetic Rim Lesion biomarkers that have become central to the 2024 Revised McDonald Criteria.
The collaboration details
VHIR will supply a curated, multi‑center dataset of MS patient MRIs, each paired with ground‑truth lesion masks created by neuroradiology experts led by Dr. Alex Rovira Cañellas. Neurophet will use the data to train, test, and refine convolutional neural networks that automatically highlight lesions, quantify disease burden, and flag high‑risk imaging signatures. The partnership is structured as a non‑exclusive research agreement, with both parties retaining rights to publish findings and integrate the resulting models into commercial workflows.
Technology under the microscope
Neurophet’s AQUA MS sits on top of the broader AQUA platform, a cloud‑native imaging suite that ingests DICOM data, runs AI pipelines, and returns structured reports via an API. The new models will extend AQUA MS’s existing FDA‑cleared 510(k) functionality (approved in October 2024) by adding two AI‑driven biomarkers:
- Central Vein Sign (CVS) – a radiological pattern that distinguishes MS lesions from mimics.
- Paramagnetic Rim Lesion (PRL) – an emerging marker of chronic active inflammation linked to disease progression.
By automating the detection of CVS and PRL, clinicians can reduce manual review time by an estimated 30 % and improve diagnostic confidence, especially in ambiguous cases.
Industry implications
The collaboration arrives at a moment when enterprise AI adoption is accelerating. Gartner predicts that by 2027, 70 % of healthcare organizations will embed AI into clinical decision support, up from 30 % in 2023. Neurophet’s move to enrich its platform with vetted, multi‑institutional data positions it alongside larger AI‑cloud players such as Google Cloud Healthcare API, Amazon HealthLake, and Microsoft Azure Health. Unlike those general‑purpose services, Neurophet offers a vertically integrated, FDA‑cleared solution that can be deployed on‑premise or in a hybrid cloud, a flexibility prized by hospitals bound by data‑sovereignty regulations.
Competitive context
Several startups—e.g., Viz.ai, Aidoc, and Qure.ai—have launched AI tools for neuro‑imaging, but most focus on acute stroke or tumor detection. Neurophet’s emphasis on chronic neuro‑inflammatory disease differentiates it in a niche that has attracted relatively little venture capital. The partnership with VHIR, a leading European MS research hub, gives Neurophet a data moat that rivals may find hard to replicate without similar academic ties. Moreover, the inclusion of CVS and PRL aligns the product with the latest diagnostic guidelines, a compliance edge that many competitors lack.
Enterprise relevance
For enterprise marketing and sales teams in the med‑tech space, the announcement provides a concrete case study of how AI can be leveraged to meet regulatory standards while delivering measurable workflow efficiencies. The collaboration also underscores the importance of co‑development with reputable research institutions—a strategy that can accelerate FDA clearance and boost credibility with health system CIOs. Companies that can showcase validated, disease‑specific biomarkers are better positioned to negotiate bundled pricing with insurers and to integrate into existing EMR ecosystems such as Salesforce Health Cloud or Adobe Experience Manager for Healthcare.
Market Landscape
The global AI‑enabled medical imaging market is projected to reach $13.5 billion by 2028, according to a recent IDC forecast, driven by rising demand for automated diagnostics and the need to offset radiologist shortages. Europe remains a hotbed for MS research, with the European MS Platform reporting a 15 % annual increase in imaging‑based clinical trials. In the United States, the prevalence of MS exceeds 1 million patients, making the U.S. market the largest commercial opportunity for AI‑driven MS tools. Neurophet’s focus on FDA‑cleared, cloud‑agnostic software aligns with the broader trend of “AI‑as‑a‑service” that major cloud providers are championing.
Top Insights
- Data partnership as a moat: Access to VHIR’s >1,000‑patient, expertly annotated MRI set gives Neurophet a competitive edge in model accuracy and regulatory confidence.
- Biomarker focus drives adoption: Automating CVS and PRL detection addresses a clear clinical need, potentially cutting radiologist review time by up to 30 %.
- Hybrid deployment wins: Offering both on‑premise and cloud options satisfies hospitals with strict data‑sovereignty policies, differentiating Neurophet from pure‑cloud rivals.
- Regulatory advantage: Building on an already FDA‑cleared platform reduces time‑to‑market for new AI modules, a critical factor in the fast‑moving med‑tech landscape.
- Enterprise narrative: Co‑development with a leading academic institute provides a compelling story for marketing teams targeting health system decision‑makers.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
